statistiche ricercatore

Continente	#
NA - Nord America	1.068
AS - Asia	370
EU - Europa	342
SA - Sud America	66
AF - Africa	51
Continente sconosciuto - Info sul continente non disponibili	28
OC - Oceania	1
Totale	1.926

Nazione	#
US - Stati Uniti d'America	1.046
SG - Singapore	137
IT - Italia	103
CN - Cina	79
VN - Vietnam	76
RU - Federazione Russa	59
BR - Brasile	51
IE - Irlanda	32
SE - Svezia	32
CI - Costa d'Avorio	29
DE - Germania	28
FI - Finlandia	22
HK - Hong Kong	22
FR - Francia	19
GB - Regno Unito	15
BD - Bangladesh	12
CA - Canada	12
IN - India	12
IQ - Iraq	8
MA - Marocco	7
PL - Polonia	6
TR - Turchia	6
UA - Ucraina	6
AR - Argentina	5
JP - Giappone	5
ZA - Sudafrica	5
AT - Austria	4
EC - Ecuador	4
EG - Egitto	3
NL - Olanda	3
PH - Filippine	3
BE - Belgio	2
CO - Colombia	2
CR - Costa Rica	2
CZ - Repubblica Ceca	2
HN - Honduras	2
ID - Indonesia	2
LY - Libia	2
MX - Messico	2
PK - Pakistan	2
TN - Tunisia	2
TT - Trinidad e Tobago	2
VE - Venezuela	2
AE - Emirati Arabi Uniti	1
AO - Angola	1
AU - Australia	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
CL - Cile	1
CW - ???statistics.table.value.countryCode.CW???	1
DZ - Algeria	1
ES - Italia	1
EU - Europa	1
GT - Guatemala	1
KE - Kenya	1
LT - Lituania	1
MD - Moldavia	1
MK - Macedonia	1
NO - Norvegia	1
OM - Oman	1
PR - Porto Rico	1
PT - Portogallo	1
RO - Romania	1
SA - Arabia Saudita	1
SI - Slovenia	1
TH - Thailandia	1
UZ - Uzbekistan	1
Totale	1.900

Nome	#
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis	262
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing.	212
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer	190
Electrolyte disorders in cancer patients: a systematic review	170
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience	170
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab	169
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis	162
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer	151
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type	149
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC	147
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?	144
Totale	1.926

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	77	0	0	0	4	1	9	8	2	16	11	7	19
2022/2023	330	18	30	15	22	11	117	0	13	51	3	43	7
2023/2024	146	23	3	7	5	16	59	1	5	0	2	1	24
2024/2025	253	43	17	3	6	8	14	17	15	42	13	36	39
2025/2026	815	67	40	40	73	91	59	149	77	69	80	25	45
2026/2027	186	32	81	22	51	0	0	0	0	0	0	0	0
Totale													1.926